Amneal Pharmaceuticals supplier risk assessment Q1-2026: 63 shipments, India-focused sourcing.
Amneal Pharmaceuticals recorded 63 shipments in Q1 2026 across six suppliers in four countries. India dominates the sourcing footprint at 73% of total shipments, with Amneal Pharmaceuticals Private Limited and Amneal Pharmaceuticals (both India-based) accounting for 44 of the 63 shipments combined. The remaining volume flows through JMS (France, 7 shipments), Japan Vilene (China, 2 shipments), Nilkamal (India, 2 shipments), and Solara Active Pharma Sciences (Sri Lanka, 1 shipment). No HS classification data was available for this period.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
One name associated with this importer matched a sanctions watchlist in Q1 2026. No suppliers registered exposure to forced-labor-adjacent supply chains under UFLPA criteria. The importer carries a B-grade compliance score of 75, reflecting moderate overall trade-risk profile.
6 distinct tier-1 suppliers in Q1 2026
| AMNEAL PHARMACEUTICALS PRIVATE LIMI | India | 24 |
| AMNEAL PHARMACEUTICALS | India | 20 |
| JMS | France | 7 |
| JAPAN VILENE | China | 2 |
| NILKAMAL | India | 2 |
| SOLARA ACTIVE PHARMA SCIENCES | Sri Lanka | 1 |
Share of Q1 2026 inbound shipments by source country
11 tier-2 + 51 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.